№ lp_2_1_09809
File format: docx
Character count: 2523
File size: 18 KB
Consent form for publication of identifying material in AJKD, including possible revisions and clarifications of the manuscript and related files, with the understanding of non-guaranteed anonymity and no financial compensation.
Year:
2023
Region / City:
United States
Topic:
Consent, Medical Publication
Document Type:
Consent Form
Institution:
American Journal of Kidney Diseases (AJKD)
Author:
Not specified
Target Audience:
Researchers, Healthcare Professionals, Nephrologists
Action Period:
Before publication
Approval Date:
Not specified
Modification Date:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2026
Region / city:
European Union
Topic:
Personalized Medicine for Cardiovascular, Metabolic, and Kidney Diseases
Document type:
Pre-proposal application form
Organization / Institution:
European Union Funding Agencies
Author:
Not specified
Target audience:
Research institutions, academic institutions, and industry partners
Duration:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Contextual description:
A pre-proposal application form for the CARMEN2026 joint transnational call for proposals aimed at personalized medicine for cardiovascular, metabolic, and kidney diseases.
Year:
2023
Region / city:
Australia
Topic:
Chronic hyperkalaemia, kidney disease, sodium zirconium cyclosilicate
Document Type:
Submission to PBAC
Agency / organization:
AstraZeneca Pty Ltd
Author:
Not specified
Target audience:
Medical practitioners, healthcare professionals
Period of validity:
Ongoing, based on PBAC recommendation and PBS listing
Approval date:
1 September 2023
Date of amendments:
Not specified
Year:
2015
Country:
New Zealand
City:
Wellington
Subject:
Chronic kidney disease
Document type:
National consensus statement
Issuing body:
Ministry of Health
Authors:
CKD Core Work Group
Target audience:
Clinicians and managers in funder and provider organisations
Healthcare setting:
Primary care
Publication date:
March 2015
ISBN:
978-0-478-44476-6
License:
Creative Commons Attribution 4.0 International
Focus population:
Adults with chronic kidney disease
Clinical scope:
Identification, classification, and management of CKD
Period covered:
Contemporary clinical practice as of 2015
Canberra Health Services Guideline Apixaban and Rivaroxaban Use in Adults with Severe Kidney Disease
Year:
2021
Region / City:
Canberra, Australia
Topic:
Pharmacology / Kidney Disease
Document Type:
Clinical Guideline
Institution:
Canberra Health Services
Author:
Not specified
Target Audience:
Medical staff and pharmacists
Period of Validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2023
Region / city:
Canberra
Subject:
Chronic Kidney Disease, Pain Management
Document Type:
Guideline
Organization / Institution:
Canberra Health Services
Author:
Unknown
Target Audience:
CHS medical staff
Effective Period:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2017
Region / City:
N/A
Topic:
Nephrology, Anaemia, Chronic Kidney Disease
Document Type:
Patient Information
Organization / Institution:
Nephrology Department
Author:
Emma Head
Target Audience:
Patients with Chronic Kidney Disease
Effective Period:
N/A
Approval Date:
N/A
Modification Date:
N/A
Year:
[year]
Region / City:
[region]
Topic:
Anticoagulation, Venous Thromboembolism, Kidney Disease
Document Type:
Clinical Practice Guideline
Institution / Organization:
UK Kidney Association
Author:
Kathrine Parker, Albert Power, Yvonne Bernes, Kate Bramham, Richard Buka, Satarupa Choudhuri, Mark Davies, Maria A Gauci, Lauren Hall, Alan Hancock, John Hartemink, Ed Jenkinson, Nicola Korn, Donna Lewis, Gregory Y.H. Lip, Katy Mills, Anneka Mitchell, Lara Roberts, Huw Rowswell, Hannah Stacey, Katherine Stirling, Jecko Thachil, Jung Tsang, Isaac Tseng
Target Audience:
Healthcare professionals in nephrology, haematology, and related fields
Period of Application:
Ongoing
Approval Date:
[month] [year]
Amendment Date:
[month] [year]
Year:
2023/2024
Region / city:
NHS England
Topic:
Healthcare, Quality and Outcomes Framework (QOF)
Document type:
Business rules, Technical specification
Organization / institution:
NHS England
Author:
General Practice Specification and Extraction Service (GPSES), NHS England
Target audience:
General practitioners, GP system suppliers
Period of validity:
2023–2024
Approval date:
01/04/2023
Amendment date:
01/04/2024
Description:
This document provides the technical business rules and dataset specifications for Chronic Kidney Disease (CKD) under the Quality and Outcomes Framework (QOF) for use by NHS England and General Practice Systems.
Year:
2021
Country:
Australia
Drug:
Dapagliflozin
Brand name:
Forxiga
Dosage form and strength:
Tablet, 10 mg
Sponsor:
AstraZeneca Pty Ltd
Indication:
Chronic kidney disease
Submission type:
Category 1 submission
Requested listing:
Authority Required (Streamlined), General Schedule
Regulatory bodies:
Pharmaceutical Benefits Advisory Committee; Therapeutic Goods Administration
Target population:
Adults with chronic kidney disease with specified eGFR and UACR ranges
Comparator:
Placebo plus standard of care
Intervention:
Dapagliflozin plus standard of care
Clinical claims:
Superior efficacy and non-inferior safety versus standard of care alone
Related indications:
Type 2 diabetes mellitus; heart failure with reduced ejection fraction
Regulatory status date:
Priority review granted 13 November 2020
Year:
2019
Region / City:
Australia
Topic:
Kidney Disease, Healthcare
Document Type:
Strategic Action Plan
Organization:
Kidney Health Australia
Author:
Professor Carol Pollock, Kidney Health Australia Board
Target Audience:
Healthcare professionals, patients, policymakers
Period of validity:
Ongoing
Approval Date:
2019
Date of amendments:
Not specified
Year:
2019
Region / city:
Australia
Topic:
Kidney Disease, Health Policy
Document Type:
Report
Organization / Institution:
Kidney Health Australia
Author:
Dr. Emma Tinning, Dr. Lisa Murphy, A/Prof Shilpa Jesudason
Target Audience:
Health professionals, policymakers, researchers, and the general public
Period of Action:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2023 – current
Region / City:
Hepburn, Victoria
Document Type:
Fellowship Description
Organization:
Elder Leadership Academy
Author:
Max Primmer
Target Audience:
Older Men, Health Professionals, Community Members
Period of Action:
Ongoing
Approval Date:
N/A
Date of Changes:
N/A
Year:
2023
Region / city:
Global
Topic:
Aquatic animal health
Document type:
Assessment report
Organization / institution:
World Organisation for Animal Health (WOAH)
Author:
Aquatic Animal Health Standards Commission
Target audience:
Veterinary and aquatic health professionals, policy makers
Period of validity:
Not specified
Approval date:
Not specified
Date of amendments:
Not specified
Year:
2015
Region / City:
Amherst College
Topic:
Healthcare, Chronic Kidney Disease, Student Engagement
Document Type:
Constitution
Organization / Institution:
Amherst College, KDSAP
Author:
Niyi Odewade
Target Audience:
Students, Faculty, Staff, Medical Professionals
Effective Period:
Ongoing
Approval Date:
August 2015
Amendment Date:
N/A
Year:
2023
Region / City:
India
Sector:
Finance, Social Impact, Environmental Sustainability
Document Type:
Terms of Reference
Organization:
International Finance Corporation (IFC)
Target Audience:
Financial institutions, market researchers, consultants, policy makers
Period of Action:
2023-2024
Approval Date:
June 30, 2023
Amendment Date:
N/A
Date:
27 September 2021
Region / City:
Melbourne
Document Type:
Legal Document
Author:
John Mark Smith
Target Audience:
Legal professionals, parties involved in the case
Period of validity:
N/A
Date of approval:
27 September 2021
Date of changes:
N/A
Publication number:
2033
Publication date:
August 2022
Authorising body:
EPA Victoria
Publisher:
EPA Victoria
Jurisdiction:
Victoria, Australia
Document type:
Technical guidance
Legal framework:
Environment Protection Act 2017
Subject matter:
Naturally occurring chemical substances; contaminated land assessment; soil and groundwater
Intended users:
Land managers, contaminated land consultants, environmental auditors, environmental practitioners
Licence:
Creative Commons Attribution 4.0
Year:
2023
Region / city:
Victoria
Topic:
Key Management Personnel (KMP) Identification
Document type:
Guidance
Authority:
Australian Accounting Standards Board (AASB)
Target audience:
Government departments and entities
Period of validity:
Ongoing
Approval date:
Not specified
Amendment date:
Not specified
Year:
2007
Region / City:
Australia
Topic:
Environmental regulations, corporate responsibility
Document type:
Guidance document
Author:
Australian Government
Target Audience:
Corporations and their legal or environmental compliance teams
Effective Period:
Ongoing
Approval Date:
Not specified
Amendment Date:
Not specified